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A B S T R A C T
Objective: To identify clinical and biomarker risk factors for preeclampsia in women with obesity and to explore
interactions with gestational diabetes, a condition associated with preeclampsia.
Study design: In women with obesity (body mass index≥ 30 kg/m2) from the UK Pregnancies Better Eating and
Activity Trial (UPBEAT), we examined 8 clinical factors (socio-demographic characteristics, BMI, waist cir-
cumference and clinical variables) and 7 biomarkers (HDL cholesterol, hemoglobin A1c, adiponectin, inter-
leukin-6, high sensitivity C-reactive protein, and placental growth factor (PlGF)) in the early second trimester for
association with later development of preeclampsia using logistic regression. Factors were selected based on
prior association with preeclampsia. Interaction with gestational diabetes was assessed.
Main outcome measure: Preeclampsia.
Results: Prevalence of preeclampsia was 7.3% (59/824). Factors independently associated with preeclampsia
were higher mean arterial blood pressure (Odds Ratio (OR) 2.22; 95% Conﬁdence Interval (CI) 1.58–3.12, per
10mmHg) and lower PlGF (OR 1.39; 95% CI 1.03–1.87, per each lower 1 log2). The association of PlGF with
preeclampsia was present amongst obese women without gestational diabetes (OR 1.91; 95% CI 1.32–2.78), but
not in those with GDM (OR 1.05; 95% CI 0.67–1.63), p=0.04 for interaction.
Conclusion: The relationship between PlGF and preeclampsia diﬀered in women with obesity according to ge-
stational diabetes status, which may suggest diﬀerent mechanistic pathways to preeclampsia. Whilst replication
is required in other populations, this study suggests that performance of prediction models for preeclampsia
should be conﬁrmed in pre-speciﬁed subgroups.
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1. Introduction
Globally, preeclampsia is one of the principal causes of maternal
and neonatal morbidity and mortality, with a prevalence of 3–5% in
unselected populations [1]. The principal feature of preeclampsia is
new onset hypertension with proteinuria after 20 weeks’ gestation. In
the absence of curative treatment, management involves stabilization of
the mother and fetus, followed by timely delivery. The cause of pre-
eclampsia remains unclear but certain co-morbidities predispose
women to an increased risk, including gestational diabetes mellitus
(GDM) and obesity, the focus of the present study [2,3].
Obesity is increasing worldwide. By 2025, it is expected that one in
every ﬁve women of reproductive age across the world will have obe-
sity of whom at least 7–9% are likely to develop preeclampsia [4]. Some
reports suggest an associated increase in the prevalence of pre-
eclampsia, however other risk factors, such as increasing maternal age
and a reduction in smoking, may have contributed [5]. Insulin re-
sistance and a mild inﬂammatory state have been implicated in the
pathophysiology of preeclampsia in women with obesity, which could
also explain the association between GDM and preeclampsia [3,6,7].
However, in a recent study we found no evidence of a link between
insulin resistance or inﬂammation biomarkers and preeclampsia in a
group of nulliparous women with obesity [8]. As women with obesity
who develop GDM have an exaggerated insulin resistance and in-
ﬂammation biomarker proﬁle [9], we hypothesized that the association
of insulin resistance and inﬂammatory biomarkers with preeclampsia
may be conﬁned to women who develop GDM.
The aim of this study was to identify clinical and biomarker risk
factors for preeclampsia in women with obesity and to explore inter-
action with GDM status. This was undertaken as a secondary analysis of
a large cohort of pregnant women with obesity, the UK Pregnancies
Better Eating and Activity Trial (UPBEAT), from whom a detailed
clinical history had been obtained and blood samples taken in the early
second trimester, prior to the development of preeclampsia [10].
2. Materials and methods
This study was a prospective cohort using data from UPBEAT, a
randomized controlled trial of a complex behavioral intervention aimed
at reducing GDM and large for gestational age infants [10]. UPBEAT
recruited pregnant women with obesity (body mass index (BMI)
≥30 kg/m2) with singleton pregnancies at 15+0–18+6 weeks’ gesta-
tion. Women were excluded if they had underlying disorders, including
pre-pregnancy diagnosis of essential hypertension, diabetes, renal dis-
ease, systemic lupus erythematosus, antiphospholipid syndrome, sickle
cell disease, thalassaemia, coeliac disease, thyroid disease, and current
psychosis; or if they were currently being prescribed metformin. De-
tailed information was collected at trial entry (15+0–18+6 weeks ge-
station) on maternal clinical characteristics, including socio-demo-
graphic information and anthropometric measures; non-fasting blood
samples were also taken. Extensive information on maternal and infant
outcomes was recorded. Research ethics committee approval was ob-
tained (UK Integrated Research Application System, reference 09/
H0802/5) and all women provided written consent.
For the purpose of the present study, women with incomplete in-
formation on preeclampsia status, oral glucose tolerance test (OGTT)
results, clinical and biomarker data were excluded. The UPBEAT in-
tervention was not associated with a diﬀerence in the prevalence of
preeclampsia or GDM [10], we therefore treated the study population
as a cohort for the purpose of this analysis.
The primary outcome of the present study was preeclampsia which
was deﬁned according to the International Society for the study of
Hypertension in Pregnancy (ISSHP) criteria: two measures of systolic
(≥140mmHg) or diastolic blood pressure (≥90mmHg) taken at least
four hours apart and the presence of proteinuria (spot urine protein/
creatinine ≥30mg/mmol [0.3 mg/mg] or ≥300mg/day or at least
1 g/L [‘2 + ’] on dipstick testing) [11]. For the purpose of this study,
preeclampsia diagnosis was reviewed based on blood pressure and
proteinuria values recorded by the research team. GDM, the pre-spe-
ciﬁed interaction analysis, was assessed by a universal screening 75 g
OGTT and diagnosis was based on the International Association of
Diabetes and Pregnancy Study Groups (IADPSG) criteria comprising
one or more positive plasma glucose values: fasting ≥5.1mmol/l, 1 h
≥10.0mmol/l, 2 h ≥8.5 mmol/l [12,13].
Potential clinical risk factors included 8 variables selected on the
basis of previously identiﬁed associations with preeclampsia and ability
to translate to clinical practice. These were: age, nulliparity, BMI, waist
circumference, known history of preeclampsia, ﬁrst degree family his-
tory of hypertension and mean arterial blood pressure. Maternal sum of
skinfold thicknesses (derived from the sum of mean triceps, biceps,
subscapular, and suprailiac measurements made by trained research
staﬀ) was also explored due to its known association with BMI. Blood
pressure was recorded using the pregnancy validated Microlife BP3BT0-
A blood pressure monitor (Microlife, Widnau, Switzerland) and ma-
ternal skinfold thicknesses (triceps, biceps, suprailiac and subscapular)
were measured in triplicate, using Harpenden skinfold Calipers (Holtain
Ltd, Felin-y-Gigfran, Crosswell, UK) [14]. Seven biomarkers were se-
lected based on either a proposed role in preeclampsia pathogenesis in
women with obesity, or a previously reported association with pre-
eclampsia in weight heterogeneous women. These were: triglycerides,
high-density lipoprotein (HDL), hemoglobin A1c (HbA1c), adiponectin,
interleukin-6 (IL-6), high sensitivity C Reactive Protein (hs-CRP), and
placental growth factor (PlGF). Biomarker measurement methodology
is described in the Appendix (Table A1).
A complete case analysis was undertaken and we compared socio-
demographic characteristics between the study population and women
excluded from this analysis because of missing data. Assumptions for
normality were checked for all predictors. Candidate biomarkers that
showed positive skew were log transformed (triglycerides, HDL, adi-
ponectin, IL-6, CRP, and PlGF). Transformation into log2 were per-
formed so that odds ratios showed the eﬀect associated with doubling
the concentration. As low values of PlGF, are associated with pre-
eclampsia, the scale was reversed, so that the odds ratio (OR) re-
presented the increase in odds of preeclampsia associated with a re-
duction in PlGF. Clinical factors and biomarkers did not vary with
gestational age at sampling, so additional correction for gestational age
was not performed.
Descriptive statistics were presented as means (SD), median (IQR)
and frequency of observations (percentages), as appropriate.
Comparisons of socio demographic characteristics and pregnancy out-
comes between women with and without preeclampsia were performed
using Chi-square tests, Wilcoxon rank-sum tests and t-tests as appro-
priate. Univariable logistic regression was used to investigate the as-
sociation between clinical risk factors and biomarkers and the risk of
development of preeclampsia later in pregnancy. Assessment of bio-
markers was corrected for multiple testing using the False Discovery
Rate (FDR) [15]. Signiﬁcant factors were identiﬁed if p < 0.05 (FDR
adjusted p-value for biomarkers) and were combined in a ﬁnal multiple
regression model for preeclampsia. To address the hypothesis that risk
factors for preeclampsia may diﬀer by GDM status, we explored the
eﬀect of pre-speciﬁed factors (PlGF, IL-6, CRP) and any signiﬁcant risk
factor in multivariable analysis on preeclampsia separately in women
with and without GDM (stratiﬁed analysis). Likelihood ratio tests were
then used to perform formal tests of interaction. Sensitivity analyses
were performed using multiple imputation by chained equations to
assess the potential for selection bias in complete case analysis. Out-
comes (preeclampsia or GDM) were not imputed and women with
missing outcomes were excluded from sensitivity analysis. Statistical
analysis was performed using Stata software, version 14.2 (StataCorp
LP, College Station, Texas). This study has been reported in line with
STROBE recommendations [16].
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3. Results
Of the 1554 participants available for analysis, a total of 730 (47%)
were excluded because of missing data for evaluation of preeclampsia
diagnosis (n= 47), OGTT results (n= 251), clinical risk factors
(n=43), and biomarker measurement (n= 537) (Fig. 1). Although no
diﬀerence was observed in age, BMI and smoking status, participants
excluded from this analysis were more likely of black ethnicity and
multiparous (Appendix; Table A2). The study population comprised
824 women; the prevalence of preeclampsia was 7.2% (59/824), in-
cluding 21 de novo cases of preeclampsia after review of clinical data.
The majority of cases presented at term (n= 49; 83.1%). The overall
prevalence of preeclampsia was similar in all UPBEAT participants
(6.3%).
Socio-demographic characteristics of women with and without
preeclampsia are shown in Table 1. The average age of all women was
30.6 (± 5.4) years. Women with preeclampsia had higher BMI in early
pregnancy and were more likely to be nulliparous. Age, education,
ethnicity and smoking status were similar between groups. Women with
preeclampsia were more likely to have labor induced (62.7% vs. 34.8%,
p < 0.01) and had a higher rate of preterm delivery (17.0% vs. 3.9%,
p < 0.01), whilst their infants had lower median birth weight (3275 g;
IQR 2700–3600 g vs. 3490 g; IQR 3168–3795 g, p < 0.01), lower
Apgar scores (at 5min < 7, 6.8% vs. 1.4%, p < 0.01), and were more
likely to be admitted to neonatal intensive care unit (NICU) (18.6% vs.
7.2%, p < 0.01). Women with preeclampsia also had a higher rate of
stillbirth or neonatal mortality (5.1% vs. 0.5%, p < 0.01). Amongst
women with preeclampsia, the prevalence of any neonatal morbidity
(combination of Apgar < 7, NICU admission or fetal/neonatal mor-
tality) was 34.8% (8/23) in women with GDM compared to 13.9% (5/
36) in women without GDM (p= 0.06).
Clinical factors and biomarkers in women with and without pre-
eclampsia are included in the Appendix (Table A3). Clinical factors
associated with preeclampsia in univariable analyses were nulliparity
(odds ratio (OR) 1.75; 95% Conﬁdence Interval (CI) 1.02–2.99), BMI
(OR 1.07; 95% CI 1.03–1.12, per kg/m2), higher sum of skinfolds (OR
1.01; 95% CI 1.00–1.02, per 1mm), waist circumference (OR 1.03; 95%
CI 1.01–1.05, per 1 cm) and mean arterial blood pressure (OR 2.43;
95% CI 1.06–1.13, per 10mmHg) (Table 2). Correcting for multiple
testing, reduced PlGF was the only biomarker associated with increased
odds of developing preeclampsia (OR 1.46; 95% CI 1.10–1.94, per log2)
in univariable analyses. In the multivariable regression, factors in-
dependently associated with preeclampsia were higher mean arterial
blood pressure (OR 2.22; 95% CI 1.05–1.12, per 10mmHg) and lower
PlGF (OR 1.39; 95% CI 1.03–1.87, per log2) (Table 2).
The prevalence of GDM was 29.6% (n= 241/824). The rate of
preeclampsia in women with GDM was 9.5% (n=23/241) and in
women without GDM, 6.2% (n= 36/583). Lower PlGF in the early
second trimester increased the odds of preeclampsia only in women
without GDM (OR 1.91; 95% CI 1.32–2.78, per log2); no association
was evident in women with GDM (OR 1.05; 95% CI 0.67–1.63, per log2)
(Fig. 2). This diﬀerence was evident in the interaction test (p= 0.04)
(Table 3). Higher IL-6 was associated with preeclampsia in women with
GDM (OR 1.85; 95% CI 1.17–2.92, per log2) but not in women without
GDM (OR 1.25; 95% CI 0.87–1.79, per log2), although this was not
signiﬁcant in the interaction test (p= 0.18). Other clinical factors and
biomarkers associated with preeclampsia in the full cohort did not
diﬀer by GDM status.
The size of associations (odds ratios) and the conﬁdence intervals
were broadly similar in the complete case analysis and in the additional
sensitivity analyses of imputed cases (Appendix; Table A4) and strati-
ﬁed analyses (Appendix; Table A5), except for nulliparity, which was
independently associated with preeclampsia with the increased sample
(sensitivity analysis).
4. Discussion
Whilst it is widely accepted that the etiology of preeclampsia is
heterogeneous, evidence to suggest that risk factors for preeclampsia
may diﬀer according to speciﬁc high-risk subgroups is relatively new,
and presents opportunities for personalized intervention strategies
[8,17]. To our knowledge, there has been no previous attempt to
Fig. 1. Study population.
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Table 1
Socio-demographic characteristics and pregnancy outcomes according to pre-
eclampsia status in women with obesity.
Variable No preeclampsia
Mean (SD) or n
(%)
n=765
Preeclampsia
Mean (SD) or n
(%)
n=59
p value a
Socio-demographic characteristics
Age 30.7 (5.4) 30.0 (4.9) 0.36
Body Mass Index b 35.0 (32.8–38.3) 37.6 (33.1–42.0) 0.01
Nulliparity 348 (45.5) 35 (59.3) 0.04
Full time education,
≥12 years
686 (89.7) 53 (89.8) 0.97
Ethnicity
Asian 51 (6.7) 3 (5.1)
Black 143 (18.7) 11 (18.6) 0.73
Other 40 (5.2) 5 (8.5)
White 531 (69.4) 40 (67.8)
Smoking at baseline 52 (6.8) 3 (5.1) 0.73
Pregnancy outcomes
Induction of labor
(n=823)
266 (34.8) 37 (62.7) <0.001
GA at delivery b, weeks
(n=823)
39.9 (38.9–40.9) 38.7 (37.7–39.7) <0.001
Preterm delivery (n= 823) 29 (3.8) 10 (17.0) <0.001
Birth weight b, grams
(n=823)
3490 (3170–3795) 3275 (2700–3600) <0.001
Major PPH c (n= 821) 115 (15.1) 12 (20.3) 0.28
Mode of delivery (n= 823)
LSCS in labor 136 (17.8) 10 (17.0)
Operative vaginal 91 (11.9) 8 (13.6) 0.29
Prelabor LSCS 148 (19.4) 17 (28.8)
Spontaneous vaginal 389 (50.9) 24 (40.7)
Apgar < 7 at 5min
(n=817)
11 (1.5) 4 (6.8) 0.003
NICU admission (n= 823) 55 (7.2) 11 (18.6) 0.002
Stillborn or neonatal death 4 (0.5) 3 (5.1) < 0.001
Abbreviations: GA – gestational age, IQR – interquartile range, LSCS – lower
segment caesarean section, NICU – neonatal intensive care unit, PPH - post-
partum hemorrhage, SD – standard deviation, wks – weeks.
a Comparisons performed using t-test or chi-squared test, as appropriate
(unless otherwise stated).
b Results presented as median (IQR).
c Major PPH deﬁned as estimated blood loss equal or above 1000 mls.
Table 2
Clinical risk factors and biomarkers at 15+0–18+6 weeks’ gestation associated with preeclampsia in women with obesity (n=824).
Univariable Analysis
OR (95% CI)
p value a p value b Multivariable Analysis
OR (95% CI)
p value c
Age, years 0.98 (0.93–1.03) 0.36
Nulliparous 1.75 (1.02–2.99) 0.04 1.50 (0.86–2.62) 0.15
BMI 1.07 (1.03–1.12) 0.002 1.04 (0.96–1.13) 0.29
Sum of skinfolds, mm 1.01 (1.00–1.02) 0.02 1.00 (0.99–1.02) 0.43
Waist, cm 1.03 (1.01–1.05) 0.01 1.00 (0.97–1.04) 0.96
Previous PE 2.53 (0.94–6.83) 0.07
FH of hypertension 1.48 (0.87–2.51) 0.15
MAP, per 10mmHg 2.43 (1.75–3.37) < 0.001 2.22 (1.58–3.12) < 0.001
HDL, per log2 of mmol/l 0.48 (0.26–0.90) 0.02 0.05
Triglycerides, per log2 of mmol/l 1.77 (1.02–3.08) 0.04 0.06
HbA1c, mmol 1.07 (1.00–1.15) 0.04 0.07
Adiponectin, per log2 of ug/ml 0.82 (0.62–1.09) 0.17 0.20
IL-6, per log2 of pg/ml 1.46 (1.10–1.94) 0.008 0.06
hs-CRP, per log2 of mg/L 1.15 (0.90–1.46) 0.27 0.27
PlGF d, per log2 of pg/ml 1.46 (1.10–1.94) 0.01 0.03 1.39 (1.03–1.87) 0.04
Abbreviations: OR – odds ratio, CI – conﬁdence interval, BMI – body mass index, PE – preeclampsia, FH – family history, MAP - mean arterial blood pressure, HDL –
high-density lipoprotein, HbA1c – Hemoglobin A1c, IL-6 – interleukin-6, hs-CRP – high sensitivity C reactive protein, PlGF – inversed placental growth factor.
a Crude p values (logistic regression).
b False discovery rate (FDR) corrected p values are shown for biomarkers (logistic regression).
c Multivariable logistic regression.
d PlGF was inversed, the eﬀect of a lower PlGF (per 1 log2 unit) is shown.
Fig. 2. Observed probability of preeclampsia (95% conﬁdence intervals) ac-
cording to concentration of placental growth factor (PlGF) at 15+0–18+6
weeks’ gestation in women with obesity with and without gestational diabetes
mellitus (GDM).
Table 3
Risk factors for preeclampsia according to GDM status in women with obesity,
and interaction test.
No GDM
OR (95% CI)
n=583
GDM
OR (95% CI)
n= 241
p value a
MAP, per 10mmHg 2.48 (1.63–3.76) 2.23 (1.30–3.82) 0.76
IL-6, per log2 of pg/ml 1.25 (0.87–1.79) 1.85 (1.17–2.92) 0.19
hs-CRP, per log2 of mg/L 1.09 (0.81–1.48) 1.21 (0.80–1.83) 0.70
PlGF b, per log2 of pg/ml 1.91 (1.32–2.78) 1.05 (0.67–1.63) 0.04
Abbreviations: OR – odds ratio, CI – conﬁdence interval, MAP – mean arterial
blood pressure, HDL – high-density lipoprotein, IL-6 – interleukin-6, hs-CRP –
high sensitivity C reactive protein, PlGF – inversed placental growth factor.
a Likelihood ratio tests for interaction.
b PlGF was inversed; the eﬀect of a lower PlGF (per 1 log2 unit) is shown.
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address risk factors for preeclampsia in women with obesity whose
pregnancies are also complicated by GDM.
Although we conﬁrmed preeclampsia risk factors previously re-
ported in a heterogeneous BMI population, notably raised mean arterial
blood pressure and a reduced concentration of PlGF in early second
trimester, we also report that PlGF, increasingly used in prediction or
diagnosis of preeclampsia [18,19], was not associated with pre-
eclampsia in women with obesity who developed GDM. There was,
however, a trend for an association between the inﬂammatory mediator
(IL-6) and preeclampsia in women who developed GDM. These data
support the hypothesis that diﬀerent mechanisms may lead to pre-
eclampsia in subgroups of women, and that in obese women who de-
velop both preeclampsia and GDM, PlGF as a predictive/diagnostic test
for preeclampsia may have limited use.
Whilst numerous epidemiological studies have demonstrated that
obesity increases the risk of preeclampsia, the mechanisms have yet to
be fully elucidated [20,21]. Obesity is characterized by insulin re-
sistance and an exaggerated state of inﬂammation and oxidative stress
which have been implicated in pathways leading to preeclampsia
[6,22]. However, in a recent study of 834 women with obesity
(BMI≥ 30 kg/m2) and 3106 lean nulliparous women (BMI 20–25 kg/
m2) from the international Screening for Pregnancy Endpoints study
(SCOPE) and in whom 53 relevant biomarkers were measured, we
found no evidence of an association between markers of insulin re-
sistance or inﬂammatory mediators measured at 14+0–16+0 weeks’
gestation with later preeclampsia in either lean women or women with
obesity [8]. Universal screening for GDM was not performed in SCOPE,
which limited the assessment of an interaction of GDM in the associa-
tion of risk factors at baseline and subsequent development of pre-
eclampsia. In contrast, an OGTT was undertaken in all women included
in the present study, enabling examination of interactions between
GDM and risk factors for preeclampsia.
The association of low PlGF with preeclampsia, which in the women
in this study occurred predominantly at term, conﬁrms our previous
observations in women with obesity from the SCOPE cohort [23], but is
developed further here by the observation that it is restricted to women
with obesity without GDM. Low values of PlGF, or the sFlt-1:PlGF ratio,
are increasingly used in the prediction, diagnosis and ‘rule-out’ of
preeclampsia [18,24–26]. If our observations were to be replicated later
in pregnancy, pre-eclampsia diagnostic or rule-out tests using PlGF
would require subgroup assessment.
Raised IL-6 has been associated previously with later development
of GDM and has been described in preeclampsia at the time of disease in
unselected populations [9,27,28]. The observed trend between IL-6
(but not hs-CRP) and preeclampsia restricted to women with obesity
and GDM warrants further study in larger cohorts [29].
Early second trimester mean arterial blood pressure was strongly
associated with preeclampsia in this multi-ethnic heterogeneous po-
pulation (Appendix; Table A2), conﬁrming many previous reports re-
cognizing that raised blood pressure in early pregnancy is a risk factor
for preeclampsia in unselected populations [25,26].
The strengths of our study include the prospective detailed data
collection ensuring almost complete ascertainment of preeclampsia and
GDM and the wide range of clinical factors, anthropometric measures
and biomarkers available. Another strength is the precise deﬁnition of
GDM using universal screening with a 75 g OGTT in accordance with
IADPSG and WHO recommendations. Measurement of sFlt-1 was not
performed as the association with preeclampsia is conﬁned to later
pregnancy (after 20 weeks) [30,31]. Limitations include the 47% (824/
1554) of participants excluded because of missing data with the po-
tential for selection bias. However, a sensitivity analysis using multiple
imputation which included 82% (1276/1554) of participants provided
similar results. We did not perform universal assessment of uterine
artery Doppler, a recognized risk factor for preeclampsia, but this re-
ﬂects current clinical practice [25,26]. Neither did we explore asso-
ciations between PlGF later in pregnancy in relation to preeclampsia
and GDM. The number of women with a diagnosis of preeclampsia may
have limited the power to detect some diﬀerences of smaller size. Given
the small numbers of cases of preeclampsia within each subgroup these
ﬁndings, whilst novel, require replication in larger studies. We also
acknowledge that the absence of a lean group for comparison in this
cohort is a limitation (i.e. no-obesity without GDM, no-obesity with
GDM).
5. Conclusion
The study of subgroups of women at high risk for preeclampsia has
contributed to improved understanding of the heterogeneous etiology
of this condition. Our results suggest that the relationship between PlGF
and preeclampsia diﬀers in women with obesity according to GDM
status, which may indicate diﬀerent pathways to disease. Studies
seeking to translate the use of PlGF as predictive test for preeclampsia
into clinical practice should consider sub-group analysis according to
obesity status.
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